The research organization ACCELLENA has begun the practical phase of implementing an open-label, multicenter Phase II clinical trial aimed at studying the safety and efficacy of the drug Ftortiazinon, 300 mg tablets, in adult patients diagnosed with chronic bacterial cystitis. The first patient has been enrolled at the research center in Perm as part of the project.
The study is initiated by the Federal State Budgetary Institution N.F. Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of Russia and involves 60 patients.
The entire project implementation cycle is managed by the ACCELLENA team, which handles medical writing, logistics, interaction with ethics committees, clinical sites support, staff training, monitoring visits, data management, biostatistics and preparation of a final report.
An enrollment of the first patient marks a significant milestone in the project, opening the active phase of recruitment. Work to expand the study's geographical coverage and include new subjects is ongoing.
The study is initiated by the Federal State Budgetary Institution N.F. Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of Russia and involves 60 patients.
The entire project implementation cycle is managed by the ACCELLENA team, which handles medical writing, logistics, interaction with ethics committees, clinical sites support, staff training, monitoring visits, data management, biostatistics and preparation of a final report.
An enrollment of the first patient marks a significant milestone in the project, opening the active phase of recruitment. Work to expand the study's geographical coverage and include new subjects is ongoing.
